IL311883A - Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues - Google Patents

Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

Info

Publication number
IL311883A
IL311883A IL311883A IL31188324A IL311883A IL 311883 A IL311883 A IL 311883A IL 311883 A IL311883 A IL 311883A IL 31188324 A IL31188324 A IL 31188324A IL 311883 A IL311883 A IL 311883A
Authority
IL
Israel
Prior art keywords
interleukin
chimeric constructs
inflammatory tissues
targeted specificity
specificity
Prior art date
Application number
IL311883A
Other languages
English (en)
Hebrew (he)
Original Assignee
Assist Publique H?Pitaux De Paris
Iltoo Pharma
Inserm Institut National De La Sant? Et De La Rech M?Dicale
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publique H?Pitaux De Paris, Iltoo Pharma, Inserm Institut National De La Sant? Et De La Rech M?Dicale, Univ Sorbonne filed Critical Assist Publique H?Pitaux De Paris
Publication of IL311883A publication Critical patent/IL311883A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL311883A 2021-10-06 2022-10-06 Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues IL311883A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306399 2021-10-06
PCT/EP2022/077847 WO2023057588A1 (en) 2021-10-06 2022-10-06 Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

Publications (1)

Publication Number Publication Date
IL311883A true IL311883A (en) 2024-06-01

Family

ID=78463430

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311883A IL311883A (en) 2021-10-06 2022-10-06 Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues

Country Status (11)

Country Link
US (1) US20240376172A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412631A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533848A (cg-RX-API-DMAC7.html)
KR (1) KR20240113459A (cg-RX-API-DMAC7.html)
CN (1) CN118414160A (cg-RX-API-DMAC7.html)
AU (1) AU2022360645A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233644A1 (cg-RX-API-DMAC7.html)
IL (1) IL311883A (cg-RX-API-DMAC7.html)
MX (1) MX2024004291A (cg-RX-API-DMAC7.html)
WO (1) WO2023057588A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402730B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194686A2 (en) * 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) * 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2026159300A1 (en) 2025-01-24 2026-07-30 Iltoo Pharma M3c65 antibody and derivatives thereof for targeting inflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
FR2869323B1 (fr) 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
US8437577B2 (en) 2009-03-05 2013-05-07 Tektronix, Inc. Methods and systems for image registration
WO2011160845A2 (en) * 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
KR102493543B1 (ko) 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
ES2982752T3 (es) 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
WO2019148204A1 (en) * 2018-01-29 2019-08-01 The Regents Of The University Of California Therapies and methods to treat tlr2-mediated diseases and disorders
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
US20230036793A1 (en) * 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs

Also Published As

Publication number Publication date
US20240376172A1 (en) 2024-11-14
JP2024533848A (ja) 2024-09-12
ZA202402730B (en) 2024-11-27
CA3233644A1 (en) 2023-04-13
MX2024004291A (es) 2024-06-28
CN118414160A (zh) 2024-07-30
AU2022360645A1 (en) 2024-05-02
WO2023057588A1 (en) 2023-04-13
EP4412631A1 (en) 2024-08-14
KR20240113459A (ko) 2024-07-22

Similar Documents

Publication Publication Date Title
EP4017503A4 (en) Ddx17 and nlrc4 targeting for inflammatory diseases
IL286711A (en) Interleukin-2 variants with modified biological activity
EP4514195A4 (en) HYGIENIC SHEET FOR ENDOSCOPY
EP3924482A4 (en) ENZYMES WITH RUVC DOMAINS
IL284447A (en) Dux4 rna silencing using rna targeting crispr-cas13b
IL280697A (en) New car constructs comprising tnfr2 domains
LT4192839T (lt) Remdesiviro tarpiniai junginiai
EP4041284A4 (en) VARIANT OF IGF2 CONSTRUCTS
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EP3924477A4 (en) ENZYMES WITH RUVC DOMAINS
EP4329877C0 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
EP3749372C0 (en) IL-12 COMPOSITIONS FOR TARGETING EDB
IL306141A (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
HUE059638T2 (hu) Ízületi gyulladásos betegségek kombinált kezelése
IL310698A (en) Cytotoxicity targeting chimeras for ccr2-expressing cells
IL286212A (en) Aav mutant having brain-targeting property
EP3890719A4 (en) VERY LONG-CHAIN FATTY ACID COMPOSITIONS
ZA202206740B (en) Interleukin 2 chimeric constructs
DK3990879T3 (da) Temperatursonde-hubs
HUE063463T2 (hu) Adalék alkalmazása üzemanyag középpárlat alacsony hõmérsékleti tulajdonságainak javítására
EP3761962A4 (en) EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
EP4122326A4 (en) OXYGEN Scavenger COMPOSITION
IL284644A (en) Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP4051021C0 (en) TOBACCO-CONTAINING AEROSOL-GENERATING COMPOSITION COMPRISING MEDIUM-CHAIN TRIGLYCERIDES
EP4504799A4 (en) CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING